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Abstract 
Glaucoma is a term describing a group of ocular disorders with multi-factorial aetiology united by a 
clinically characteristic intraocular pressure-associated optic neuropathy. It is not a single entity and 
is sometimes referred to in the plural as the glaucomas. All forms are potentially progressive and can 
lead to blindness. The diverse conditions that comprise glaucoma are united by a clinically 
characteristic optic neuropathy, known as glaucomatous optic neuropathy (GON). Evidence suggests 
that the primary site of neurological injury is at the optic nerve head (ONH). This single fact, 
sometimes conceptualized as common end-organ damage, enables the conditions to be grouped, 
irrespective of the causal mechanism(s). The term experimental glaucoma implies model 
resemblance to the human condition. We propose that “experimental glaucoma” be restricted to 
animal models with demonstrable features of GON and/or evidence of a primary axonopathy at the 
ONH. A fundamental inadequacy in this framework is any reference to the pathogenesis of GON, 
which remains unclear. 
  
Glaucoma (in all its forms) is the leading cause of irreversible blindness worldwide1, 2 and is a 
research focus for many ophthalmic and neuroscience-based laboratories. The definition of its most 
common subtype, primary open-angle glaucoma (POAG), appears inconsistently in the literature,3 
and the fact that glaucoma refers to a group of related conditions may not be appreciated by non-
clinicians. The status of intraocular pressure (IOP) as a defining characteristic of glaucoma has 
evolved over time.  From the latter part of the 19th century until the last quarter of the 20th century, 
IOP was a defining characteristic of glaucoma; however, the recognition of elevated IOP in the 
absence of “glaucomatous optic neuropathy” (GON) and conversely GON in the absence of an 
elevated IOP relegated IOP to risk factor status rather than a defining feature. Although the 
American Academy of Ophthalmology in its Preferred Practice Patterns® series does not define 
glaucoma per se, it currently views IOP as a risk factor, amongst many, for primary open-angle 
glaucoma (POAG).4 But IOP reduction remains the only treatment strategy for all types of glaucoma. 
The decade-old epidemiological definition has enhanced management, with its angle-closure-related 
nomenclature widely adopted clinically.5 Others have called for a consensus definition for clinical 
glaucoma.3, 6 Herein, we have set out to provide a framework for conceptualizing glaucoma. We do 
not claim that a consensus has been reached amongst the glaucoma community, nor do we intend this 
to be the last word on the matter. We are optimistic that an improved understanding of glaucoma will 





The definition of glaucoma 
The concise definition of glaucoma is a follows: 
Glaucoma is a term describing a group of ocular disorders with multi-factorial aetiology united by a 
clinically characteristic intraocular pressure-associated optic neuropathy. 
This characteristic optic neuropathy is termed "glaucomatous optic neuropathy" (GON), and includes 
structural and functional features. While it has the advantage of concision, this definition is circular. 
Arguably it is an “analytical proposition”, which whilst true, contains no useful information: the 
subject is contained within the predicate, and it logically distills to “glaucoma is glaucoma”.   
To avoid this conundrum we must contain the "characteristics" within the definition. 
Hence, the formal definition is as follows: 
Glaucoma describes a group of ocular disorders of multi-factorial aetiology united by a clinically 
characteristic optic neuropathy with potentially progressive, clinically visible changes at the optic 
nerve head (ONH), comprising focal or generalized thinning of the neuroretinal rim with excavation 
and enlargement of the optic cup, representing neurodegeneration of retinal ganglion cell axons and 
deformation of the lamina cribrosa; corresponding diffuse and localized nerve-fibre-bundle pattern 
visual field loss may not be detectable in early stages; while visual acuity is initially spared, 
progression can lead to complete loss of vision; the constellation of clinical features is diagnostic.   
 
In practice, the concise definition is adequate, but requires that the communicator and the intended 





Definition of Basic Glaucoma Subtypes and Associated Conditions 
Elevated intraocular pressure (IOP) means the IOP exceeds the 97.5
th percentile for the population 
under consideration. 
Ocular Hypertension (OHT) describes the condition where the IOP is elevated, for any or no 
apparent reason, but glaucomatous optic neuropathy is not detectable. 
Glaucoma Suspect describes an eye (or individual) with features suggestive of glaucoma, but where 
the clinician believes that there is insufficient evidence to commit to a diagnosis of glaucoma.     
Primary Open-angle Glaucoma (POAG) is a singular subtype of glaucoma with an open angle, and 
if the IOP is elevated, no cause is found.     
Normal Tension/Pressure Glaucoma (NTG/NPG) may be singular subtype of POAG where the IOP 
is never observed to be elevated. 
Secondary Open-angle glaucoma (SOAG) refers to a collection of glaucomas with an open-angle, the 
IOP is or has been elevated and a cause for the elevated IOP is clinically evident.  
Primary Angle-closure glaucoma (PACG) is a singular subtype of glaucoma with anatomical 
iridotrabecular contact, potentially involving multiple mechanisms; the IOP is always elevated at 
some stage. 
Secondary angle-closure glaucoma (SACG) is a collective subtype of glaucoma with iridotrabecular 
contact not from any form of anatomical predisposition: an alternative pathological mechanism is 
responsible; and the IOP is or has been elevated at some stage.  
 
Notes on the definitions 
The definition that we have offered for glaucoma contains the salient features of the condition:  
“Glaucoma” is not a single entity. It refers to a group of ocular disorders; as these disorders have 
diverse features, perhaps “the glaucomas” as a plural would be better. The term applies equally well 
to an eye or to an individual. If one eye of an individual has glaucoma, the individual is considered 
to have glaucoma. Even though we use the terms “glaucoma” and “glaucomas” interchangeably, it is 
preferable to specify the particular subtype under consideration.  
IOP is a continuous biological variable and follows an approximately Gaussian distribution in the 
population, with rightward skewing. An elevated IOP is a statistical concept with clinical 
implications and defined as an IOP greater than the 97.5th percentile for the population; this accords 
with epidemiological definitions.5 By defining elevated IOP in percentile terms, it doesn’t matter if 
the distribution is not Gaussian. But including an elevated IOP as a part of the definition presents a 
problem; GON occurs in individuals who never have a recorded IOP that is elevated: so-called 
"normal tension glaucoma" (NTG). Whilst, the existence of NTG as a separate disease process is 
disputed,7 reducing the IOP in individuals with NTG can modify the natural history of the disease8; 
therefore, we believe it is accurate to say that even NTG is "associated with IOP". Similarly, IOP 
reduction attenuates the progression of POAG.9 All secondary glaucoma subtypes have an elevated 
IOP.5 IOP reduction is the only current evidence-based treatment strategy for all types of glaucoma, 
including NTG, (a study to determine the efficacy of IOP reduction for secondary glaucoma would 
be unethical because there is no clinical equipoise.5) Hence, glaucoma in all its forms is associated 
with IOP, albeit the IOP is not statistically elevated in the case of NTG.     
All forms are potentially progressive and can lead to blindness. We prefer "potentially progressive" 
rather than "progressive" because this term makes three important points: (1) Glaucoma can be 
diagnosed in the absence of documented progression. On first presentation of an individual with 
characteristic features of GON, it is unnecessary to wait for observed changes to confirm diagnosis. 
Changes are assumed to have occurred as part of the natural history of the condition. (2) Progression 
is not always observed as part of the natural history. Temporary conditions may occur at the ONH 
which produce GON, but which do not progress. This is a theoretical possibility with empirical 
support. In the Normal Tension Glaucoma Study, approximately 50% of untreated individuals had 
localized visual field deterioration by 7 years.10 Similarly, a period of elevated IOP may produce 
GON that does not progress if the IOP naturally returns to normal. However, it seems prudent for 
clinicians to regard all glaucoma as potentially progressive. (3) The notion that glaucoma is 
potentially, but not inevitably, progressive underlies the current treatment paradigm: IOP reduction 
can attenuate, if not halt, disease progression in both “high pressure” and “normal pressure” 
glaucomas.8, 9  
The diverse conditions that comprise the glaucomas are united by a clinically characteristic optic 
neuropathy. This single fact, sometimes conceptualized as common end-organ damage,5 enables the 
conditions to be grouped, irrespective of the causal mechanism(s). Clinically visible changes occur at 
the ONH. “Optic disc” is broadly synonymous with the ONH, but "disc" suggests a two-dimensional 
structure as viewed with the monocular direct ophthalmoscope. "ONH" is a better description for the 
3-dimensional structure. Overwhelmingly, clinical impression sites the primary pathology at the 
ONH. This notion is supported by limited experimental evidence. Quigley et al demonstrated axonal 
transport obstruction at the ONH in a primate model of glaucoma.11, 12 In a rodent model (DBA/2J 
mouse), the earliest observable pathology may occur at the distal RGC axon (closer to its synapse),13 
but the site of primary injury in this glaucoma model is the (ONH).14, 15 Hence GON is primarily an 
"optic nerve headopathy".  
Excavation and enlargement of the optic cup, with focal or generalized thinning of the neuroretinal 
rim are the hallmarks of GON. These characteristic changes to the ONH take some time to develop. 
An acute obstruction of blood flow to the ONH typically does not produce changes characteristic of 
GON. Thus an IOP sufficiently elevated to obstruct ONH blood flow acutely will produce an 
ischaemic optic neuropathy, not glaucoma.  
Pathologically, there is neurodegeneration of all RGC compartments. Because glaucoma is a primary 
axonopathy at the ONH, the RGC axons are the first cellular compartment to be involved. There is a 
surprising paucity of published histological analysis of the retina, but the available evidence 
indicates that the RGC dendrites are affected at an early stage of the disease 16, 17 with eventual loss 
of RGC bodies that has features of apoptotic cell death.18 Degeneration of the lateral geniculate 
nucleus has been reported in human and experimental primate glaucoma.19-21 Recently, functional 
magnetic resonance imaging has demonstrated changes in the higher visual centres in human and 
experimental glaucoma.22, 23 Oddly, there is only a single case report of a post-mortem examination 
on a human brain from a patient with glaucoma, demonstrating trans-synaptic degeneration back to 
the visual cortex.24 Whether or not other neuronal cell types are affected in human glaucoma requires 
further study.  
The RGC axons are not the only structures affected at the ONH. Deformation and particularly 
backward bowing of the lamina cribrosa are visible clinically. There is evidence for astrocyte25-27 and 
microglial activation at the ONH.28-31 Morphological connective tissue changes at the ONH 
associated with excavation and undermining of the rim are almost pathognomonic. 32   
That structural changes to neurones produce corresponding functional changes is fundamental to the 
pathophysiological interpretation of clinical findings. At some level, structure must correlate with 
function. But this correlation is not always demonstrable clinically. The apparent dissociation 
between structure and function sometimes observed may result from different scales of measurement 
for these parameters and/or the lack of highly sensitive functional tests with narrow inter-subject 
variability.  The associated functional deficits include scotomata in a pre-chiasmal, nerve fibre 
bundle-type distribution, matching the observed changes at the ONH. Diffuse suppression of the 
visual field may be an early feature of glaucoma. Localized field defects typically begin in the mid-
peripheral or paracentral region. Other functional deficits, including a reduction in contrast 
sensitivity are observed but less frequently clinically tested.33, 34 Snellen visual acuity deteriorates 
late in the disease. Whether glaucomatous visual dysfunction can precede any structural 
glaucomatous change at the ONH is unclear. Evidence against this assertion comes from our 
collective clinical experience: we rarely, or perhaps never, witness definitively glaucomatous visual 
fields in the absence of any possible glaucomatous ONH changes. But evidence supporting this 
assertion comes from the Ocular Hypertension Treatment Study (OHTS). Participants on enrollment 
had an elevated IOP, but optic discs deemed "normal by 2 independent, masked, certified readers at 
the Optic Disc Reading Center". The study was designed to determine the effect of IOP reduction 
compared with the natural history based on the proportion of individuals converting to GON. The 
first sign of GON in 41.7% of the treated group and 32.6% of the control group was visual field 
change. Does this mean visual field changes frequently precede optic disc changes in glaucoma 
development? Perhaps the OHTS results are more likely from many participants having borderline 
optic discs at enrollment, which in the presence of normal fields were arguably normal, but by 
Bayesian-type clinical decision making, in the presence of early glaucomatous field changes would 
be reconsidered as glaucomatous. Why structural changes should be the harbinger of functional 
changes, rather than vice versa is unclear. Given that RGCs may be "sick" and dysfunctional before 
they undergo degeneration and severe structural change, it is surprising that functional deficits are 
not routinely seen before loss of axons. As we do not, perhaps our functional measurements do not 
capture early functional changes. 
Any of the glaucomas can progress to complete loss of vision, and as a group, the glaucomas are the 
leading cause of irreversible blindness worldwide. 
Glaucoma is a clinical diagnosis. No investigations are required to make the diagnosis, but ONH 
imaging techniques, including stereophotography, complement the clinical diagnosis and provide 
permanent records, which on repetition, can be assessed for change. Diagnosis is based on the 
constellation of clinical features. This point has important ramifications: (1) there is no single 
measurement that can capture all glaucoma. (2) it cannot be diagnosed by an untrained observer. (3) 
the clinical evidence in support of a diagnosis of glaucoma is not an all or none phenomenon.  
The Diagnosis of Glaucoma 
The structural features of GON coupled with the functional features form the basis for the diagnosis. 
Rarely, both the structural and functional features of GON can be mimicked by other conditions. A 
masquerading condition cannot be ruled out with mathematical certainty.35 Hence, based on the 
evidence available, a clinician develops a degree of belief about the likelihood that a patient does 
have glaucoma. This is a form of Bayesian decision making. Because this degree of belief is on a 
continuum, exemplified by the design of a recent online GON teaching tool,36 the more relevant 
information that the clinician has, the better. Because clinicians may interpret data differently, levels 
of belief about the glaucoma status of individuals may differ amongst clinicians. This variability and 
the subjective nature of the Bayesian approach gives rise to the clinical entity of “glaucoma 
suspects”. These individuals have an increased risk of developing GON. They comprise a 
considerable portion of clinical practice. For clinical trials where the glaucoma status of a subject is 
critical information, either at the outset or endpoint, the gold standard diagnostic assessment may be 
the consensus of expert opinion. 
As glaucoma is a clinical diagnosis, the diagnosis focuses on assessing whether or not the 
characteristic features of GON are present. Additional information, if available, is not disregarded. In 
reality, the prudent clinician evaluates all the available evidence and formulates a degree of belief 
about glaucoma likelihood. This probability ranges from nil to certainty (or at least beyond 
reasonable doubt). This is a Bayesian interpretation rather than a frequentist interpretation of 
probability. In practice, reasonable management decisions do not necessarily require a definitive 
diagnosis. A patient may be managed appropriately on the “balance of probabilities”. However, for 
the purposes of clinical studies it is often necessary to categorize individuals as having “definite 
glaucoma”. The minimum possible clinical information that is both necessary and sufficient to 
commit to a diagnosis of glaucoma is based on the observation of characteristic ONH features or 
consistent, characteristic visual field changes of GON, in the absence of another explanation for the 
functional defect.  
An example of how complementary information can affect the diagnosis of glaucoma is provided by 
the methodology of the Early Manifest Glaucoma Treatment Study (EMGTS).9 Entry criteria were 
largely based on the presence of repeatable “glaucomatous visual field defects”, which were “outside 
normal limits”, but the methodology also stated: “A “borderline” classification (on Humphrey 
perimetry 24-2 testing) was acceptable only if obvious localized glaucomatous optic disc cupping 
was present in an area corresponding to the visual field defect.” Hence, the Investigators permitted 
knowledge of the ONH appearance to influence the interpretation of the visual fields. In Bayesian 
terms, the posterior probability (of glaucoma) was influenced by the prior probability (the visual 
fields) and new data (the ONH appearance). Because glaucoma is defined in terms of GON, 
information about other clinical features of the condition is not necessary for diagnosis, but, in 
practice, it does influence diagnostic decision making. Although for the purposes of a clinical study, 
it may be reasonable to restrict clinical information to the features of GON, this is an artificial 
situation that does not reflect clinical practice. For example, knowledge of the IOP, or family history 
of an individual could reasonably influence interpretation of the ONH appearance and/or visual 
fields. It is a popular misconception that the IOP is irrelevant to the diagnosis: it is not necessary, but 
it is not irrelevant.     
Basic Classification of the Glaucomas 
Perhaps the most clinically useful classification of the glaucomas is that devised by Barkan which 
divides glaucoma into angle-closure or open-angle.37 A further subdivision produces either primary 
or secondary glaucomas (Figure 1). In the latter, the clinician detects an "elevated IOP" during the 
disease and finds a cause; in the former, if the IOP is ever elevated, no cause is found. The division 
of primary glaucoma into open-or angle closure sub-types is an extremely useful clinical distinction; 
however, primary angle-closure glaucoma (PACG) is more aptly categorized with the secondary 
glaucomas: the angle is closed owing to an anatomical predisposition creating iridotrabecular contact 
(ITC). In secondary angle-closure glaucomas, the cause for the ITC is deemed to be pathological 
rather than anatomical, but the terminology has a historical basis, not a logical one. 
The association between primary open-angle glaucoma (POAG) and IOP is more tenuous, because 
of the subset with NTG. Additionally, we have another large group of individuals with elevated IOP, 
but no GON: so-called ocular hypertension (OHT). The definition of glaucoma circumvents OHT 
because in OHT, GON is not present. OHT is a risk factor for GON, and the higher the IOP, the 
greater the risk. Hence, the principal problem in our taxonomy of glaucoma is NTG. All other forms 
of glaucoma have an elevated IOP, at least at some point during the disease. Entrenched in the 
ophthalmic lexicon, it requires a definition, remaining cognizant that its existence is disputed.7 We 
accept the merit of Wilson’s “Myth of 21” in reference to an IOP of 21 mmHg as a cut off separating 
POAG from NTG,7 but conversely, note  that POAG at low IOPs may have clinical features different 
from POAG at elevated IOPs.35, 38, 39 Whether the features of NTG are distinct enough to warrant it 
to be called a “disease” in its own right is controversial.   
The glaucomas are further clinically divided into acute and chronic based on duration. The dividing 
line seems arbitrary, but in humans, a chronic disease is measured in months to years rather than 
days to weeks. Primary and secondary glaucoma can be acute or chronic. If glaucoma requires GON 
as a defining criterion, what is the minimum time required for recognizable GON to develop.     
We conceptualize a “space” (confined by IOP and time) within which GON can develop bounded at 
the earliest duration by the minimum time taken to develop features of GON and bounded by an 
upper limit of IOP beyond which the ONH is rendered acutely ischaemic and beyond which the 
features of GON do not develop. The longest duration over which GON can develop is simply 
bounded by the age at death. The minimum IOP at which GON can develop within a lifetime 
remains unclear.  
How does ONH appearance after an acute IOP elevation differ from that after chronic elevation? 
Clinically, an acute IOP elevation often produces pallor without excavation; by definition, this is not 
glaucoma. The little evidence available supports this impression.40-42 Thus an attack of acute angle 
closure in the absence of any chronic IOP elevation frequently will not produce GON and, if it 
doesn’t, by definition is not one of the glaucomas. It must be considered as a related but distinct 
condition.    
 
Experimental Glaucoma  
Experimental models of relevance to glaucoma 
A model is a representation of reality. Although the concept of “validity” in science is somewhat 
nebulous, the scientific community generally considers a model as valid if it mimics what it is 
supposed to. Researchers “validate” their own model and the medical literature abounds with 
publications describing validation of various experimental models. Whether a model is clinically 
useful is a different matter. A biological model is useful clinically if information derived from it 
could improve patient outcomes. This includes models designed to improve understanding of 
biological mechanisms and to test treatments. A Drosophila model of glaucoma genetics is 
potentially valid and useful if it generates data relevant to the genetics of human glaucoma. A wide 
variety of experimental models could be relevant to glaucoma. They could be both useful and valid 
in the context of glaucoma; it would be imprudent to ignore information from a model because it did 
not resemble the clinical condition. However, extrapolation of laboratory-based data to the human 
situation can be problematic. 
Models of RGC injury 
Models of RGC injury, both in vitro and in vivo, are routine in neuroscience research. Researchers 
using these models often assert the possible relevance to human glaucoma of data thus generated. 
Because glaucoma is a RGC axonopathy, this conclusion seems reasonable, but  conversely, the data 
may not have relevance. The possible irrelevance to clinical disease of lab-based models, particularly 
in in vitro models is particularly evident in the neurological field; it highlighs the frustrated 
translation of laboratory-based neuroprotection to human conditions. 
As argued by Weinreb and Lindsey, in vitro models often provide methodological advantages and 
are a powerful research tool, but are generally less relevant to clinical glaucoma than in vivo models. 
43 
 
What is Experimental Glaucoma? 
The term experimental glaucoma implies model resemblance to the human condition. Although 
Drosophila research could be a valid and useful model for certain aspects of glaucoma, it should not 
be regarded as experimental glaucoma. Similarly,  in vitro models do not merit the term experimental 
glaucoma.  An experimental model of glaucoma (as apposed to a model with relevance to glaucoma) 
should fit the definition of glaucoma we have suggested. Experimental models meeting that standard 
are rare, but naturally occurring glaucoma in animals is well described. 
Naturally occurring “glaucoma” in animals 
Naturally occurring sight-threatening, IOP-associated ocular disease is not unique to humans. 
Veterinarians use the term “glaucoma” to describe a form of eye disease recognized in several types 
of domesticated animals, and characterized by IOP-induced optic nerve degeneration (and in some 
species retinal degeneration).44, 45 All these conditions are associated with an elevated IOP and 
almost all have an underlying cause for the elevated IOP or are associated with angle closure and 
thus could be considered “secondary glaucomas”. The beagle dog has a primary open-angle 
glaucoma with no antecedent cause for IOP elevation, but its features and natural history are 
different from human POAG.46 Cupping of the ONH is a characteristic feature; naturally occurring 
GON in certain animal species with a well-formed lamina cribrosa resembles human GON. To our 
knowledge, NTG has never been reported in any animal other than humans. Although the naturally 
occurring glaucoma in a colony of purpose-bred beagle dogs has been considered as a potential 
model for human glaucoma,47 most glaucoma animal research has been on models of induced 
glaucoma in rodents, rabbits  and primates. 
GON in experimental models 
A number of animal models of glaucoma have been developed over the past 3 decades, some more 
successful than others. The most common strategy to induce features of GON has been to elevate the 
IOP, but chronic optic nerve ischaemia has also been reported to cause GON in rabbits and primates. 
The primate model involving trabecular meshwork laser was developed in the 1970s and still 
remains a viable model,48, 49 but has largely been replaced by logistically and ethically more 
appealing rodent models. A variety of techniques have been used to obstruct the trabecular 
meshwork in rats, including cautery of “episcleral” veins, 50 translimbal laser photocoagulation,51, 52 
and hypertonic saline injection.53 More recently, micobeads have been used to obstruct the 
meshwork and placement improved by using paramagnetic beads. 53 Of these, only translimbal laser 
has stood the test of time and is in widespread use. Hypertonic saline injection appears to be 
effective, but is technically demanding and not widely used.  Magnetic beads remain relatively 
untested. Surgically induced mouse models of experimental glaucoma have been reported, but do not 
appear to have been widely adopted. 54-56 A number o f genetic mouse models exist, 57 and the most 
well-characterized is the DBA/2J mouse. 58 This mouse develops an age-related elevation of IOP and 
RGC loss. Its chronicity is appealing in terms of its resemblance to human glaucoma, but non-
glaucomatous pathological retinal features have been described, 59 making its relevance unclear. 
Although animal models of experimental glaucoma can be used to test hypotheses, we must be 
careful about drawing inferences about human glaucoma pathogenesis and potential therapy from 
animal models.  If a successful treatment in an animal model of elevated IOP (not counting reduction 
of IOP) could be translated to human glaucoma then the model would have been convincingly 
validated. To our knowledge, this challenge remains unmet. 
ONH changes described as “cupping” have been reported in rats,60-62 mice 61, 63, rabbits,64, 65 and 
most convincingly in primates.43, 66 The most common strategy to induce features of GON has been 
to elevate the IOP, but chronic optic nerve ischaemia has also been reported to cause GON in rabbits 
and primates.64, 65 We propose “experimental glaucoma” be restricted to animal models with 
demonstrable features of GON and/or evidence of a primary axonopathy at the ONH.14    
In conclusion, we provide a conceptual framework for clinical and experimental glaucomas. A 
fundamental inadequacy in this framework is any reference to the pathogenesis of GON. However, 
pathogenesis remains poorly understood and cannot be incorporated into a definition. Conceivably, a 
unifying mechanism may ultimately explain all GON. Conversely, a raft of mechanisms may be 
responsible for GON and the notion of glaucoma as a single concept may become a historical 
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